LABP

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting

Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation

Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

Landos Biopharma Announces Pricing of Initial Public Offering